Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) Director Jon Faiz Kayyem purchased 69,686 shares of the firm's stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of $14.23 per share, with a total value of $991,631.78. Following the purchase, the director now owns 51,093 shares of the company's stock, valued at approximately $727,053.39. This represents a -374.80 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Inhibrx Price Performance
NASDAQ:INBX opened at $14.08 on Friday. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95. The business has a fifty day moving average of $15.61 and a 200-day moving average of $17.20.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its stake in shares of Inhibrx by 8.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company's stock worth $518,000 after purchasing an additional 1,112 shares in the last quarter. Black Maple Capital Management LP bought a new position in Inhibrx during the first quarter valued at about $555,000. Finally, Alpine Global Management LLC acquired a new position in Inhibrx during the first quarter worth about $1,224,000. Institutional investors own 82.46% of the company's stock.
Inhibrx Company Profile
(
Get Free Report)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
